An Estimate of Cancer Mortality Rate Reductions in Europe and the US with 1,000 IU of Oral Vitamin D Per Day

2007 ◽  
pp. 225-234 ◽  
Author(s):  
William B. Grant ◽  
Cedric F. Garland ◽  
Edward D. Gorham
Keyword(s):  
Vitamin D ◽  
Mortality Rate ◽  
Cancer Mortality ◽  
Oral Vitamin ◽  
The Us

scholarly journals Leading cancers contributing to educational disparities in cancer mortality in the US, 2017

2021 ◽  
Author(s):  
Diana R. Withrow ◽  
Neal D. Freedman ◽  
James T. Gibson ◽  
Mandi Yu ◽  
Anna M. Nápoles ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High School ◽  
Mortality Rate ◽  
Cancer Mortality ◽  
Death Certificate ◽  
Bachelor's Degree ◽  
Educational Disparities ◽  
Individual Level ◽  
Death Certificate Data ◽  
The Us

Abstract Purpose To inform prevention efforts, we sought to determine which cancer types contribute the most to cancer mortality disparities by individual-level education using national death certificate data for 2017. Methods Information on all US deaths occurring in 2017 among 25–84-year-olds was ascertained from national death certificate data, which include cause of death and educational attainment. Education was classified as high school or less (≤ 12 years), some college or diploma (13–15 years), and Bachelor's degree or higher (≥ 16 years). Cancer mortality rate differences (RD) were calculated by subtracting age-adjusted mortality rates (AMR) among those with ≥ 16 years of education from AMR among those with ≤ 12 years. Results The cancer mortality rate difference between those with a Bachelor's degree or more vs. high school or less education was 72 deaths per 100,000 person-years. Lung cancer deaths account for over half (53%) of the RD for cancer mortality by education in the US. Conclusion Efforts to reduce smoking, particularly among persons with less education, would contribute substantially to reducing educational disparities in lung cancer and overall cancer mortality.

scholarly journals Explaining state-level differences in brain cancer mortality in the United States by population ancestries: a spatial approach

2015 ◽  
Vol 1 (1) ◽  
pp. 12 ◽  
Author(s):  
Ari Voutilainen ◽  
Paula R. Sherwood
Keyword(s):  
United States ◽  
Mortality Rate ◽  
Brain Cancer ◽  
Cancer Mortality ◽  
State Level ◽  
The United States ◽  
The State ◽  
Foreign Born ◽  
The Us ◽  
The Brain

To some extent, the spatial differences in brain cancer mortality rate appear to arise from the difference in the mortality betweenethnic groups. In the United States (US), for example, brain cancer mortality rate is higher among White Non-Hispanic thanother groups. The US brain cancer mortality data (age-adjusted and pooled over 2007-2011) were gathered from the State CancerProfiles web site. The brain cancer mortality rates were associated with the geographic distribution of different ancestral andethnic groups at the state-level by applying three different statistical analyses to find out the most evident spatial patterns. Thegeographic distribution of the brain cancer mortality was related to the proportion of foreign-born Black and White in the USpopulation so that the mortality rate was high in the states were the proportion of foreign-born was low and vice versa. The onlyancestries which increased the mortality among White Non-Hispanic in the US population were from a relatively restricted area inEurope including Germany, Czech Republic, the Netherlands, Luxemburg, Belgium, and the Nordic countries except for Iceland.This study gave reasons for the discussion about the possible existence of population-level genetic susceptibilities to the braincancer and/or higher risk of mortality. Brain cancer mortality in general as well as the present results apply mainly to gliomas.

scholarly journals Identification of Mortality Risks in the Advancement of Old Age: Application of Proportional Hazard Models Based on the Stepwise Variable Selection and the Bayesian Model Averaging Approach

Nutrients ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 1098
Author(s):  
Ewelina Łukaszyk ◽  
Katarzyna Bień-Barkowska ◽  
Barbara Bień
Keyword(s):  
Vitamin D ◽  
Mortality Rate ◽  
Plasma Level ◽  
Variable Selection ◽  
Lymphocyte Count ◽  
Bayesian Model ◽  
Bayesian Model Averaging ◽  
Multivariable Analysis ◽  
Model Averaging ◽  
Nutritional Risk Index

Identifying factors that affect mortality requires a robust statistical approach. This study’s objective is to assess an optimal set of variables that are independently associated with the mortality risk of 433 older comorbid adults that have been discharged from the geriatric ward. We used both the stepwise backward variable selection and the iterative Bayesian model averaging (BMA) approaches to the Cox proportional hazards models. Potential predictors of the mortality rate were based on a broad range of clinical data; functional and laboratory tests, including geriatric nutritional risk index (GNRI); lymphocyte count; vitamin D, and the age-weighted Charlson comorbidity index. The results of the multivariable analysis identified seven explanatory variables that are independently associated with the length of survival. The mortality rate was higher in males than in females; it increased with the comorbidity level and C-reactive proteins plasma level but was negatively affected by a person’s mobility, GNRI and lymphocyte count, as well as the vitamin D plasma level.

scholarly journals The Clinical Effect of Oral Vitamin D2 Supplementation on Psoriasis: A Double-Blind, Randomized, Placebo-Controlled Study

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Wareeporn Disphanurat ◽  
Wongsiya Viarasilpa ◽  
Panlop Chakkavittumrong ◽  
Padcha Pongcharoen
Keyword(s):  
Vitamin D ◽  
Placebo Group ◽  
Adverse Events ◽  
Clinical Effect ◽  
Vitamin D Supplementation ◽  
P Value ◽  
Vitamin D2 ◽  
Oral Vitamin ◽  
Pasi Score ◽  
The Mean

Background. There are limited randomized controlled trials of oral vitamin D supplementation in psoriasis, especially in Asia, and the results are inconclusive. Objective. To investigate the clinical effect of oral vitamin D supplementation on psoriasis. Methods. Patients with psoriasis were randomized to receive vitamin D2 60,000 IU or similar-looking placebo pills once every 2 weeks for 6 months. The primary outcome was improvement of the Psoriasis Area and Severity Index (PASI) score at 3 and 6 months after treatment. Serum levels of 25(OH)D, calcium, phosphate, parathyroid hormone, and C-reactive protein and adverse events were monitored. The chi-square test, Fisher’s exact test, Student’s t-test, and Spearman’s correlation analysis were used in statistical analysis. Results. Of 50 subjects screened, 45 were eligible and randomized to the oral vitamin D2 group (n=23) or placebo group (n=22). At enrollment, the mean PASI score was 4.45, and 26.7% of patients had vitamin D deficiency. At 3 months, the oral vitamin D2 group had significantly higher PASI improvement than the placebo group (mean PASI improvement: 1.43 versus [vs.] -0.33, p-value=0.034; mean %PASI improvement: 34.21% vs. -1.85%, p-value=0.039). The mean serum 25(OH)D level was significantly higher in the oral vitamin D group than in the placebo group (27.4 vs. 22.4 ng/mL, p-value=0.029). Serum 25(OH)D concentrations were significantly inversely correlated with PASI scores at the 6-month follow-up. No major adverse event was observed overall. Conclusion. Oral vitamin D2 supplementation in patients with psoriasis increased the serum vitamin D level and significantly improved the treatment outcome without increasing adverse events. Trial Registration. This trial is registered with Thai Clinical Trials Registry TCTR20180613001.

Serum Vitamin D and Cancer Mortality in the NHANES III Study (1988–2006)

2010 ◽  
Vol 20 (9) ◽  
pp. 720
Author(s):  
D.M. Freedman ◽  
A.C. Looker ◽  
C.C. Abnet ◽  
M.S. Linet ◽  
B.I. Graubard
Keyword(s):  
Vitamin D ◽  
Cancer Mortality ◽  
Serum Vitamin ◽  
Nhanes Iii ◽  
Serum Vitamin D

Low Dose Depot Oral Vitamin D3 Versus Daily Oral Vitamin D3 for Treating Nutritional Rickets: A Randomized Clinical Trial

2021 ◽  
pp. 1-18
Author(s):  
Ravneet Kaur Saluja ◽  
Pooja Dewan ◽  
Sunil Gomber ◽  
SV Madhu ◽  
Shuchi Bhatt ◽  
...  
Keyword(s):  
Vitamin D ◽  
Alkaline Phosphatase ◽  
Vitamin D3 ◽  
Low Dose ◽  
Care Hospital ◽  
Oral Vitamin ◽  
Nutritional Rickets ◽  
Vitamin D Levels ◽  
Radiological Healing ◽  
25 Oh Vitamin D

Abstract Objective: To compare the efficacy of daily versus low dose depot oral vitamin D3 for treating nutritional rickets. Design: Randomized Controlled Trial Setting: Paediatrics department of a tertiary care hospital catering to semi-urban and rural population in Delhi, India Methods: We randomized 66 children aged 3 months to 5 years with nutritional rickets to receive either daily oral vitamin D3 drops (3-12 months: 2000 IU; >12 months-5y: 4000 IU; n=33) for 12 weeks duration, or a single oral depot dose of vitamin D3 granules (3-12 months: 60,000 IU; >12 months-5y: 150,000 IU; n=33). Results: Participants in both groups had comparable demographic characteristics, laboratory features and radiological severity of rickets. 33 participants in each group received the assigned intervention and all were followed up till 12 weeks. At 12 weeks follow up, children in both groups showed a significant improvement in all biochemical parameters [serum calcium, phosphorus, alkaline phosphatase, parathormone and 25(OH) vitamin D levels] as well as radiological healing. At 12 weeks, the mean (SD) serum 25(OH) vitamin D levels (nmol/L) were statistically comparable in both groups [daily: 120.2 (83.2), depot: 108 (74), P=0.43] and 31 (94%) children in each group had radiological healing (Thacher score <1.5). Two children in each group persisted to have raised alkaline phosphatase and one child each in the daily group continued to have hypocalcemia and hypophosphatemia at 12 weeks. Conclusion: Low dose oral depot vitamin D3 is an effective alternative to daily oral vitamin D3 for nutritional rickets.

Sign in / Sign up

Export Citation Format

Share Document